Lupus & antiphospholipid syndrome
Clinical outcomes of patients receiving long-term fondaparinux for thrombotic antiphospholipid syndrome
Authors' conclusion
Thrombotic recurrence was infrequent, and the number of major bleeding events appeared comparable to conventional therapies.
Study context
- Population
- Patients with venous or arterial thrombotic APS treated with long-term fondaparinux at a single centre in the UK175 patient-years on fondaparinux
- Participants
- 46 patients
- Outcome
- Thrombosis recurrence and bleeding
Methodological detailssingle-centre, Outcomes reviewed using electronic patient records
- Single-centre
- Outcomes reviewed using electronic patient records
Main finding
As reported in the abstract
Thrombosis recurrence
| Group | Value | events/100-patient years |
|---|---|---|
| Fondaparinux | 1% | 0.6 |
Fondaparinux
Value1%
events/100-patient years0.6
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Fondaparinux treatment duration | Fondaparinux median 2.7 (IQR 1.4–4.8) years/patient |
- Fondaparinux treatment duration — Total patient-years using fondaparinux
- 175
Prior vitamin-K antagonists (VKA) as first-line anticoagulation
- Patients with VKA as first-line anticoagulation
- 43 (93%)
- Median VKA duration, years (IQR 4.0 - 9.8)
- 6.5
- All patients received fondaparinux as second-to fourth-line anticoagulation
Safety
| Outcome | Values |
|---|---|
| Major bleeding | Fondaparinux 7% · events/100-patient-years 1.1 |
| Clinically relevant non-major (CRNM) bleeding | Fondaparinux 10.9% · events/100-patient-years 2.9 |
| Minor bleeding | Fondaparinux 17.4% |
Risk factors for bleeding
- Age >65 years associated with bleeding
- P = 0.047
- Concurrent antiplatelets associated with major/clinically relevant non-major (CRNM) bleeding
- P = 0.011
- Increasing age associated with bleeding (logistic regression), OR
- 1.097, p = .009
Original publication
Clinical outcomes of patients receiving long-term fondaparinux for thrombotic antiphospholipid syndrome. Lupus. Published 16 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →